Overall, our findings indicate that ERK3 expression correlates with a more aggressive breast cancer phenotype, as evidenced by increased expression in metastatic samples, higher tumour grade, and poorer survival outcomes in breast cancer patients, regardless of subtype, although more commonly associated with TNBC. This evidence concerns the gene MAPK12 and breast cancer.